Update in Endocrinology
Authors: Janet A. Schlechte
Journal: Annals of Internal Medicine (1998)

Updates1 March 1998Update in EndocrinologyJanet A. Schlechte, MD and Robert Kreisberg, MDJanet A. Schlechte, MDFrom the University of Iowa, Iowa City, Iowa; and Baptist Health System, Birmingham, Alabama.Search for more papers by this author and Robert Kreisberg, MDFrom the University of Iowa, Iowa City, Iowa; and Baptist Health System, Birmingham, Alabama.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-5-199803010-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Advances in endocrinology in 1996 occurred in many areas. First, another drug was added to the growing list of agents used to treat type 2 diabetes mellitus. Second, an additional agent was found to be effective in decreasing low-density lipoprotein (LDL) cholesterol and triglyceride levels and thus may provide more effective prevention of atherosclerotic vascular disease. Third, the bisphosphonates, especially the oral drug alendronate, were shown to benefit patients with a broad array of bone diseases. In addition, 1996 was a year of studies that contributed to the debate over the use of human growth hormone. Finally, estrogen therapies were ...References1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20:1183-97. Google Scholar2. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997; 20(Suppl 1):S1-70. Google Scholar3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977-86. Google Scholar4. Colwell JA. The feasibility of intensive insulin management in non–insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med. 1996; 124:131-5. Google Scholar5. The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association. Diabetes Care. 1996; 19(Suppl 1):S54-61. Google Scholar6. Schorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996; 44:751-5. Google Scholar7. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995; 333:853-61. Google Scholar8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-7. Google Scholar9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9. Google Scholar10. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995; 15:678-82. Google Scholar11. Triglyceride, high-density lipoprotein, and coronary artery disease. Consens Statement. 1992; 10:1-28. Google Scholar12. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteporosis Treatment Study Group. N Engl J Med. 1995; 333:1437-43. Google Scholar13. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freed-holm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335:1016-21. Google Scholar14. Greenberger NJ. Update in gastroenterology. Ann Intern Med. 1997; 127:827-34. Google Scholar Author, Article, and Disclosure InformationAffiliations: From the University of Iowa, Iowa City, Iowa; and Baptist Health System, Birmingham, Alabama.Corresponding Author: Janet Schlechte, MD, Clinical Research Center, Room 157, MRF, University of Iowa, Iowa City, IA 52242.Current Author Addresses: Dr. Schlechte: Clinical Research Center, Room 157, MRF, University of Iowa, Iowa City, IA 52242. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1998Volume 128, Issue 5Page: 378-385KeywordsBoneBone densityDrugsEstrogensGlucoseGrowth hormoneHemoglobinHormonal therapyInsulinType 2 diabetes Issue Published: 1 March 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...